Skip to content
The Nexus
DossierENTITY

pharmaceutical merger

Coverage of pharmaceutical merger in the Nexus archive.

Earliest in view: Aug 3 · 07:08 UTCMost recent: Aug 3 · 07:08 UTC
Co-mentioned in this coverage
AstraZenecaorganization2Bristol Myers Squibborganization2Pascal Soriotperson2Princetonplace2
Recent coverage
  • BUSINESSAug 3 · 07:08 UTCGUARDIAN US
    AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger

    AstraZeneca is in talks to acquire Bristol Myers Squibb in a potential $400bn merger, creating the world’s fourth-largest drugmaker. The deal would combine AstraZeneca's nearly £196bn market value with BMS's $133bn valuation.

  • BUSINESSAug 3 · 07:08 UTCTHE GUARDIAN WORLD
    AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger

    AstraZeneca is in talks to acquire Bristol Myers Squibb in a potential $400bn merger, creating the world’s fourth-largest drugmaker. AstraZeneca, the UK’s second-biggest listed company, has a market value of nearly £196bn, while BMS, based in Princeton, is valued at $133bn.

pharmaceutical merger · Dossier · The Nexus